Could these FTSE 100 giants boost your portfolio higher?

Should you be buying these three FTSE 100 (INDEXFTSE: UKX) stocks for their income potential?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

FTSE 100 (INDEXFTSE: UKX) stocks can provide great returns for investors. Through income and growth the stocks can be a stable way to get rich slowly. 

Commodity giant

Glencore (LSE: GLEN) has been under the spotlight for over a year now. Commodity prices across the board fell sharply, which dragged the share price of Glencore down to all-time lows. However, since then the company has done a lot counter criticism of its business and it has come a long way since City analysts were saying it could go to zero. Since 1 January the share price has climbed 125% and analysts are now tagging the stock with price targets over 250p. The company has looked at the issue of its debt pile and divested a number of assets to pay off debt. I believe that the major mining company could be a good way to ride strengthening commodity prices that many expect in the next few years. The stock is coming from a very low price so it could see an explosive price rise soon. 

Defensive pharma

GlaxoSmithKline (LSE: GSK) is a favorite of UK income fund managers and quite rightly so. It holds great defensive qualities and I believe it has less risk than its FTSE 100 peer AstraZeneca. Glaxo shares are currently yielding over 4%, which is a decent income considering we live in a world of low interest rates. For income investors this looks like a top stock to own for its dividend and growth potential. The pipeline of new drugs that Glaxo has is very encouraging and the company believes there could be multiple blockbuster drugs on the way. This pipeline will add to profitability for the firm. While currently the shares are trading on 17 times forward price-to-earnings, Glaxo looks set to reap the rewards of its R&D success and I think the shares look cheap. 

UK housebuilding play

Persimmon (LSE: PSN) is about to become a great income stock due to the huge dividend scheme the company is about to begin. The shares are on a yield of over 5% and have nearly recovered since the Brexit vote shock. The UK has a fundamental housing shortage, which was addressed by Chancellor Philip Hammond this week. When setting out his new £5bn housing fund he said “my message today is clear: it’s time to get building”. This fund is for small businesses to build 25,000 homes by 2020 and 225,000 in the longer term. This is a clear indication that the housebuilding sector in the UK has a lot of work to do. Persimmon is a great way to play housebuilding in the UK and receive some income at the same time. 

I believe that these three giants will provide investors with good capital growth over the next few years and should outperform the wider market. In the case of Glaxo and Persimmon, investors will receive some chunky dividend payouts too. 

Jack Dingwall has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

Up 6%, can this ‘gritty’ stock continue outperforming the rest of the FTSE 250?

ITV's share price is soaring as investors react to a resilient performance in 2025. The question is, can the FTSE…

Read more »

Investing Articles

How much income could £20k in a Stocks and Shares ISA give you today?

As the clock ticks on this year's Stocks and Shares ISA allowance, Harvey Jones looks at how investors could use…

Read more »

Investing Articles

What next for the Endeavour Mining share price after a record-breaking set of results?

Since March 2025, Endeavour Mining’s share price has risen 175%. Do the gold miner’s latest results provide any clues as…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

How are Rolls-Royce shares looking in March 2026?

March promises to be an interesting time for Rolls-Royce shares, but should investors be worried or calm about developments?

Read more »

Black woman using smartphone at home, watching stock charts.
Investing Articles

3 these stocks are smashing BAE Systems shares – are they worth considering today? 

Harvey Jones looks at the impact of current events on BAE Systems shares this week, and highlights some FTSE 100…

Read more »

Santa Clara offices of NVIDIA
Investing Articles

At a forward P/E of 17, is Nvidia stock now a screaming buy?

Stephen Wright outlines why Nvidia stock could be better value now than it has been in a long time, despite…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

I asked ChatGPT to name the most undervalued share on the UK stock market. Here’s what it said…

Always on the lookout for value shares to add to his portfolio, James Beard turned to a well-known artificial intelligence…

Read more »

High flying easyJet women bring daughters to work to inspire next generation of women in STEM
Investing Articles

Are easyJet shares easy money at 425p?

While other airline stocks have soared since the pandemic, easyJet shares have remained grounded. Is the share price set for…

Read more »